Analgesic company Lotus Clinical Research revealed on Tuesday the election of Robert (Bob) Dworkin, PhD as director of its Chronic Pain Research.
In the senior position in the company, Dr Dworkin will lead the company's current chronic pain research programmes to expand its chronic pain expertise and capabilities, identify factors that increase the assay sensitivity of clinical trials to detect differences between an active and a placebo control or comparison treatment, lead chronic pain development efforts as well as assist with further building its CRO infrastructure to further expand its resources and drive anticipated growth.
Currently, Dr Dworkin is the professor of Anesthesiology and Perioperative Medicine, Neurology and Psychiatry, professor in the Center for Health + Technology as well as director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry.
Presently, Dr Dworkin is the director of the Analgesic, Anesthetic and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA); Special Government Employee of the US FDA Center for Drug Evaluation and Research; As well as Associate Editor of Pain and a member of the Editorial Boards of Canadian Journal of Pain and Journal of Pain.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study